Source: Υπουργείο Υγείας (CY) Revision Year: 2020 Publisher: Delorbis Pharmaceuticals Ltd., 17 Athinon Street, Ergates Industrial Area, 2643 Ergates, P.O. Box 28629, 2081 Lefkosia, Cyprus, European Union
Zobral 5 mg Film-coated tablets.
| Pharmaceutical Form |
|---|
|
Film-coated tablet. White, round, biconvex, film-coated tablets. |
Each film-coated tablet contains 5 mg of levocetirizine dihydrochloride.
Excipient(s) with known effect: 79.00 mg lactose monohydrate/tablet.
For the full list of excipients, see section 6.1.
| Active Ingredient | Description | |
|---|---|---|
| Levocetirizine |
Levocetirizine, the ® enantiomer of cetirizine, is a potent and selective antagonist of peripheral H1-receptors. Pharmacodynamic studies in healthy volunteers demonstrate that, at half the dose, levocetirizine has comparable activity to cetirizine, both in the skin and in the nose. |
| List of Excipients |
|---|
|
Tablet core: Lactose monohydrate Film-coating: Opadry Y-1-7000 or AquaPolish 010 white [hypromellose, titanium dioxide (E171), macrogol 400] |
Ζobral 5 mg film-coated tablets are supplied in blister packs of Aluminium/Aluminium containing 1, 2, 4, 5, 7, 10, 14, 15, 28, 30 film-coated tablets.
Not all pack sizes may be marketed.
Delorbis Pharmaceuticals Ltd., 17 Athinon Street, Ergates Industrial Area, 2643 Ergates, P.O. Box 28629, 2081 Lefkosia, Cyprus, European Union
Zobral 5 mg film-coated tablets: 021149
Date of first authorisation: 16 December 2011
| Drug | Countries | |
|---|---|---|
| ZOBRAL | Cyprus, Malta |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
